BioData World West: Pre-Conference Workshop


BioData is thrilled to announce groundbreaking partnerships with NASA,  the National Cancer Institute,  and the American Heart Association.  BioData World West and NASA GeneLab will be presenting an exclusive big data workshop and pre-conference day at NASA Ames Research Center* in Silicon Valley, California.

Biologists who study life in space and on Earth are joining the big-data club. With the advent of high-throughput genomics, scientists are starting to grapple with massive data sets, and encountering challenges with handling, processing, and moving information. 
Workshop sessions will be centered around the pursuit of innovation, the discovery of new data sources, and new methods of collaboration. 
*Note: Attendees of the pre-conference workshop at NASA Ames Research Center who register after February 9, 2018 must be U.S. citizens


BioData West- NASA Ames Satellite Conference & Workshops


Opening Remarks & Registration

Collaborative Scientific Innovation & Translational Medicine Stream

MORNING BRIEFING: The next evolutionary leap of technology exploitation- unprecedented speed, efficiency and agility

  • Why have present process improvements in technology exploitation only addressed peripheral aspects of the process - sociological, psychological, and financial - and therefore at best only had a minor positive impact?
  • How does the Automated Innovation Revolution enable us to address technology exploitation directly?
  • How the Automated Innovation Process developed in the U.S. intelligence community and was used on highest priority White House initiatives including: Stealth, Star Wars and advanced materials.

AHA Precision Medicine Platform Hands-on Workshop

This workshop will introduce the AHA Precision Medicine Platform, an online data marketplace for researchers and clinicians, that accelerates solutions for patients by making big data accessible.  The American Heart Association Institute for Precision Cardiovascular Medicine partnered with Amazon Web Services (AWS) for their cloud computing capabilities to create the AHA Precision Medicine Platform.  Here, millions of data points are centralized on a secure platform for researchers to search, discover, connect and analyze newly unlocked data access to cutting-edge tools in a forum that fosters collaboration to drive solutions to treat and prevent heart disease and stroke.

AHA Mantra-
"The Institute’s goal is to move toward an open data and open science framework, where scientists work together to solve the biggest challenges.  Through new ways of conducting research and strategic collaborations, the AHA seeks to save and extend lives of people currently destined to be afflicted with cardiovascular diseases."
Collaborative Scientific Innovation & Translational Medicine Stream

KEYNOTE: Quantum supremacy: checking a quantum computer with a classical supercomputer

As microelectronics technology nears the end of exponential growth over time, known as Moore’s law, there is a renewed interest in new computing paradigms such as quantum computing.   A key step in the roadmap to build a scientifically or commercially useful quantum computer will be to demonstrate its exponentially growing computing power.     I will explain how a 7 by 7 array of superconducting xmon qubits with nearest-neighbor coupling, and with programmable single- and two-qubit gate with errors of about 0.2%, can execute a modest depth quantum computation that fully entangles the 49 qubits.  Sampling of the resulting output can be checked against a classical simulation to demonstrate proper operation of the quantum computer and compare its system error rate with predictions.  With a computation space of 2^49 = 5 x 10^14 states, the quantum computation can only be checked using the biggest supercomputers.  I will show experimental data towards this demonstration from a 9 qubit adjustable-coupler “gmon” device, which implements the basic sampling algorithm of quantum supremacy for a computational (Hilbert) space of about 500.  We have begun testing of the quantum supremacy chip.  

Collaborative Scientific Innovation & Translational Medicine Stream

Blockchain Disruption & Data Donation: How Blockchain Will Change Our Industry

  • Developing a smart-contract between patient and healthcare stakeholders that makes it easy to aggregate health data in a secure, trusted, automated, and error-free way to enforce rules, privacy, and regulations in a mutually agreed upon manner
  • Enabling patients to aggregate their data from diverse health sources and share what they choose with their physicians and researchers
  • Putting the patient in control of their health and well-being, rather than being along for the ride
Collaborative Scientific Innovation & Translational Medicine Stream

PANEL: Integrating data sets across communities

  • How tranSMART and I2B2 are connecting communities 
  • Case studies on tranSMART and its benefits 
  • How can you integrate tranSMART into your industry?
Collaborative Scientific Innovation & Translational Medicine Stream

Cross Ecosystem Collaboration for Precision Medicine

  • How will intelligent formularies with tiers based on cohorts of genomic profiles, adherence characteristics, and EHR records change health systems?
  • Integrated and cross-matched data from claims, EMR combined with pre-approval safety and efficacy data and post marketing surveys to better stratify the patient population into subgroups to design specific interventions including but not limited to: Modification of Formulation, Companion Diagnostics, supplementary drugs to ameliorate side effects, Medication Adherence Reminders, Education
  • How could interventions in the context of targeted Phase IV trials be used to negotiate agreements on drug pricing and formulary placement?
Collaborative Scientific Innovation & Translational Medicine Stream

Open source collaboration and the cloud- Building next generation infrastructure for the world's researchers

  • Understanding the power of the cloud infrastructure to bolster collaboration efforts
  • How to transfer from latent infrastructure into the cloud
  • Sharing data lakes - where we are and what we have to do to progress
Collaborative Scientific Innovation & Translational Medicine Stream

How open source platforms and collaboration are changing the work carried out between NASA institutions and NCI

  • What are the advantages of partnerships?
  • Different partnering models 
  • Sharing data in a fair manner

Lunch Break

Collaborative Scientific Innovation & Translational Medicine Stream

Cardio Genomics eXchange commons (CGX): A cloud-based collaboration platform for the analysis and exchange of genome sequencing data

  • Development of a ‘Genome Dashboard’ that allows users to interactively explore genome sequencing data and identify disease-causing variants in individuals with cardiovascular disease (CVD). 
  • Integrating informatics resources that provide information about the clinical interpretation of specific genomic findings previously reported in humans
  • Merging Genome Dashboard into the cloud-based American Heart Association Precision Medicine Platform to create a genomics platform called CardioGenomics eXchange commons (CGX).
  • Creating a cloud-based data commons where researchers can collaboratively analyze and share genomic data from CVD patients to advance precision medicine initiatives and accelerate genetic findings associated with heart disease

DATATHON ON OPEN TARGETS: In partnership with EMBL- EBI and Sanger Institute

Part 1: Educating on the open targets platform
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.
Visit the Open Targets Platform which provides an integration of public domain data to enable target identification and prioritisation.
Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from four complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.
Our goals are to:
  • Systematically find the best targets to safely & effectively treat disease
  • Help others find good targets
  • Get those targets adopted into drug discovery pipelines
We currently focus on oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease
Instructors and Leaders:
Ian Dunham, Scientific Director, Open Targets, EMBL-EBI
Matthew Nelson, Head of Genetics, GSK

Part 2: Advance module
Integrating your expertise and AI approaches into the Open Targets platform
Collaborative Scientific Innovation & Translational Medicine Stream

Movement to Value Based Care from Fee For Service Care

  • Creating the Foundation for Data and Analytics
  • Data Democracy and the Changing the Analytics Culture
  • Leveraging Data External to Healthcare
Collaborative Scientific Innovation & Translational Medicine Stream

PANEL: Pre-competitive collaboration

  • How to effectively partner with other industry members to advance research whilst maintaining a competitive edge?
  • Case studies of operative frameworks and pre-competitive collaboration between industry partners.
  • Technologies used to assist with pre-competitive collaboration
Mauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences)
Collaborative Scientific Innovation & Translational Medicine Stream

Leveraging private information retrieval techniques to enable interrogation of protected genomic data

  • Protecting genomic information while stored, in transit, and in use is of growing importance.
  • Advances in private information retrieval (PIR) have opened doors for the use of protected data without the need to expose the underlying information.
  • How might homomorphic encryption and other PIR methods be leveraged to enable multi-party genomic comparisons while maintaining data privacy?
Collaborative Scientific Innovation & Translational Medicine Stream

Precision FDA- Taking Genomic Testing to the Next Level

  • How the FDA is creating a modern, flexible and dynamic regulatory system for NGS
  • Ways to develop these standards, which can be used by test developers to ensure their tests produce accurate and reliable results
  • How the aggregation of clinical information in curated databases will create a “data commons” that will serve as a reliable source of scientific evidence that test developers could use to demonstrate that NGS test results are relevant to a person’s disease or outcome
Collaborative Scientific Innovation & Translational Medicine Stream

Open systems to advance biomedical research

  • Sharing knowledge to overcome research barriers
  • Establishing methodological standards through living benchmarking of algorithms
  • Leveraging technology to actively collaborate with research participants
Collaborative Scientific Innovation & Translational Medicine Stream

Investing in healthcare- What you need to be successful with a VC

  • What do pharmaceutical companies and VC’s want to invest in?
  • How are we seeing digital investments paying off across pharma and healthcare?
  • What factors are required to gain successful investment from pharmaceuticals?
Vibhor Gupta, Entrepreneur In Residence, Nexgen Capital Ventures
Collaborative Scientific Innovation & Translational Medicine Stream

VC and Investors Showcase

15:50- SpliceCore: Drug Target Discovery with Splicing AI
Martin Akerman, CTO, Cofounder, Envisagenics
16:00-  Autism Diagnostics Technologies
Andrew Stewart, CEO and Founder, Autism Diagnostics
16:10 - Mendel.AI
Karim Galil, CEO and Founder, Mendel.AI
16:20 – Elastic Genomics
Chris Probert, Founder, Elastic Genomics (in stealth mode)
16:30- Improve patient identification in cardiovascular by using machine learning – concrete case
Adrien Rousset, Innovation Manager, Amgen
16:40- Neuroscence Inc
Yasaman Soudagar, CEO and Founder, Neurescence Inc
16:50-  ProteinQure Inc
Mark Fingerhuth, CEO and Founder, ProteinQure Inc


last published: 15/Feb/18 18:00 GMT


BioData Congress West